Efficacy and Safety of Mesotherapy With 0.5% Minoxidil Versus Topical 2% Minoxidil for Female Androgenetic Alopecia: A Randomized Controlled Trial
Dermatologic Therapy · 2026-01 · 2026 (1)
DOI: 10.1155/dth/2938873 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Dermatologic Therapy, online erschienen am 25.04.2026. Verfasst von Xiaodan Wang und 5 weiteren Autor:innen. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: China Primary Health Care Foundation.
Abstract (Originalsprache)
Objective
To evaluate the efficacy and safety of mesodermal injection of low‐concentration minoxidil versus topical minoxidil in treating female androgenetic alopecia (FAGA).
Methods
This single‐blind, randomized, controlled trial enrolled 40 FAGA patients divided into experimental ( n = 20) and control groups ( n = 20). The experimental group received mesodermal injections of 0.5% minoxidil solution once every 1–4 weeks for 16 weeks, while the control group applied topical 2% minoxidil solution twice daily for 16 weeks. The primary efficacy endpoints were changes in trichoscopic parameters (e.g., hair density and diameter) before and after treatment. The secondary endpoints comprised hairline height and physician/patient assessments.
Results
After 16 weeks of treatment, the experimental group demonstrated significantly greater increases versus the control group in hair density (8.70 ± 6.17 versus 4.50 ± 2.98 hairs/cm 2 , respectively; p = 0.009), hair coverage ( p = 0.004), and hairline height reduction (4.81 ± 0.60 mm versus 3.95 ± 0.82 mm; p = 0.002). Physician assessments indicated greater improvement in the experimental versus control groups ( p = 0.04), while patient self‐assessments showed no significant difference between the groups. No serious adverse events occurred in either group.
Conclusion
For patients with FAGA, 0.5% minoxidil mesotherapy demonstrated superior efficacy versus conventional topical therapy in promoting hair growth, improving hair quality, and lowering the hairline, with good safety. This therapy is an effective treatment option. Trial Registration: China Clinical Trial Registry: ChiCTR2500110837
Förderung
- China Primary Health Care Foundation
Zitieren
APA
Wang, X., Weng, W., Yan, Z., Li, J., Song, B. B., & Zhu, W. (2026). Efficacy and Safety of Mesotherapy With 0.5% Minoxidil Versus Topical 2% Minoxidil for Female Androgenetic Alopecia: A Randomized Controlled Trial. Dermatologic Therapy, 2026(1). https://doi.org/10.1155/dth/2938873
Vancouver
Wang X, Weng W, Yan Z, Li J, Song BB, Zhu W. Efficacy and Safety of Mesotherapy With 0.5% Minoxidil Versus Topical 2% Minoxidil for Female Androgenetic Alopecia: A Randomized Controlled Trial. Dermatologic Therapy. 2026;2026(1). doi:10.1155/dth/2938873
BibTeX
@article{Wang2026,
author = {Wang, Xiaodan and Weng, Wenjia and Yan, Zhenzhen and Li, Juan and Song, Bing Bing and Zhu, Wei},
title = {Efficacy and Safety of Mesotherapy With 0.5% Minoxidil Versus Topical 2% Minoxidil for Female Androgenetic Alopecia: A Randomized Controlled Trial},
journal = {Dermatologic Therapy},
year = {2026},
volume = {2026},
number = {1},
doi = {10.1155/dth/2938873}
}
EUVIMED